{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:24Z","timestamp":1784667684643,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.autrev.2025.103763","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T17:19:31Z","timestamp":1738689571000},"page":"103763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Complement-coagulation crosstalk in idiopathic membranous nephropathy: The potential pathogenesis and therapeutic perspective"],"prefix":"10.1016","volume":"24","author":[{"given":"Zikang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0010","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1300738","article-title":"Deficiency of phospholipase A2 receptor exacerbates ovalbumin-induced lung inflammation","volume":"191","author":"Tamaru","year":"2013","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/j.ajkd.2015.10.031","article-title":"Pregnancy in a patient with primary membranous nephropathy and circulating anti-PLA2R antibodies: a case report","volume":"67","author":"Al-Rabadi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2025.103763_bb0030","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3389\/fimmu.2019.01326","article-title":"Membranous nephropathy (MN) recurrence after renal transplantation","volume":"10","author":"Passerini","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12016-019-08741-0","article-title":"Complement system: a neglected pathway in immunotherapy","volume":"58","author":"Bordron","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101627","article-title":"Complement component C3: a structural perspective and potential therapeutic implications","volume":"59","author":"Geisbrecht","year":"2022","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00281-017-0643-z","article-title":"How novel structures inform understanding of complement function","volume":"40","author":"De Jorge","year":"2018","journal-title":"Semin Immunopathol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0055","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.molimm.2007.11.003","article-title":"The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)bb)","volume":"45","author":"Bexborn","year":"2008","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103763_bb0060","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.imbio.2012.07.008","article-title":"The tick-over theory revisited: is C3 a contact-activated protein?","volume":"217","author":"Nilsson","year":"2012","journal-title":"Immunobiology"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2025.103763_bb0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","article-title":"Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc\u03b3 receptor activation pathways","volume":"9","author":"Lilienthal","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0080","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11255-021-02997-2","article-title":"Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy","volume":"54","author":"Ji","year":"2022","journal-title":"Int Urol Nephrol"},{"issue":"16","key":"10.1016\/j.autrev.2025.103763_bb0090","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2025.103763_bb0095","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and Mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2025.103763_bb0100","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fimmu.2016.00157","article-title":"Alternative pathway dysregulation and the conundrum of complement activation by IgG4 immune complexes in membranous nephropathy","volume":"7","author":"Borza","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952235","article-title":"The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly IgG4 in membranous nephropathy","volume":"13","author":"Manral","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101341","article-title":"Regulation of regulators: role of the complement factor H-related proteins","volume":"45","author":"Cserhalmi","year":"2019","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0115","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12014-022-09365-x","article-title":"Comparative proteomic analysis of glomerular proteins in primary and bucillamine-induced membranous nephropathy","volume":"19","author":"Kaga","year":"2022","journal-title":"Clin Proteomics"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0125","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.kint.2021.05.033","article-title":"Local complement factor H protects kidney endothelial cell structure and function","volume":"100","author":"Mahajan","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/ki.2010.132","article-title":"Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice","volume":"78","author":"Fakhouri","year":"2010","journal-title":"Kidney Int"},{"issue":"25","key":"10.1016\/j.autrev.2025.103763_bb0135","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0140","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2215\/CJN.16631020","article-title":"Limited significance of Antifactor H antibodies in patients with membranous nephropathy","volume":"16","author":"Sethi","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.autrev.2025.103763_bb0145","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1056\/NEJMc1905608","article-title":"More about factor H autoantibodies in membranous nephropathy","volume":"381","author":"Valoti","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0150","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.kint.2022.07.035","article-title":"Factor H related proteins modulate complement activation on kidney cells","volume":"102","author":"Renner","year":"2022","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.autrev.2025.103763_bb0155","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022722118","article-title":"Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage","volume":"118","author":"Malik","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0160","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2021101318","article-title":"Factor H-related protein 1 drives disease susceptibility and prognosis in C3 Glomerulopathy","volume":"33","author":"M\u00e1rquez-Tirado","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"10.1016\/j.autrev.2025.103763_bb0165","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","article-title":"Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome","volume":"114","author":"Abarrategui-Garrido","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0175","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0180","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ekir.2022.02.002","article-title":"Comparison of complement pathway activation in autoimmune glomerulonephritis","volume":"7","author":"Genest","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0185","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103763_bb0190","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","author":"Gao","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41419-022-04737-5","article-title":"Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103763_bb0205","article-title":"Impact of structural modifications of IgG antibodies on effector functions","volume":"14","author":"Damelang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","article-title":"Complement activation and effector pathways in membranous nephropathy","volume":"105","author":"Kistler","year":"2024","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0215","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.kint.2019.07.014","article-title":"The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery","volume":"96","author":"Van De Logt","year":"2019","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.autrev.2025.103763_bb0220","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0225","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae104","article-title":"Combined evaluation of glomerular phospholipase A2 receptor and immunoglobulin G subclass in membranous nephropathy","volume":"17","author":"Ueki","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.autrev.2025.103763_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1324804","article-title":"Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation","volume":"2019","author":"Lateb","year":"2019","journal-title":"J Immunol Res"},{"issue":"44","key":"10.1016\/j.autrev.2025.103763_bb0235","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406192121","article-title":"Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding","volume":"121","author":"Frischauf","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2025.103763_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front Immunol"},{"issue":"Suppl. 4","key":"10.1016\/j.autrev.2025.103763_bb0245","first-page":"S44","article-title":"Complement-driven hemolytic uremic syndrome","volume":"98","author":"Leon","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0250","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1681\/ASN.2018050554","article-title":"Novel approaches to control of the alternative complement pathway for the treatment of C3 Glomerulopathies","volume":"29","author":"Daha","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0255","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"issue":"51","key":"10.1016\/j.autrev.2025.103763_bb0260","doi-asserted-by":"crossref","first-page":"50819","DOI":"10.1074\/jbc.X300009200","article-title":"A brief historical review of the waterfall\/cascade of blood coagulation","volume":"278","author":"Davie","year":"2003","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0265","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol Rev"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"10.1016\/j.autrev.2025.103763_bb0275","doi-asserted-by":"crossref","first-page":"10952","DOI":"10.1016\/S0021-9258(19)86616-4","article-title":"The contribution of bovine factor V and factor Va to the activity of prothrombinase","volume":"254","author":"Nesheim","year":"1979","journal-title":"J Biol Chem"},{"issue":"4794","key":"10.1016\/j.autrev.2025.103763_bb0280","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1126\/science.3029867","article-title":"The regulation of natural anticoagulant pathways","volume":"235","author":"Esmon","year":"1987","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.autrev.2025.103763_bb0285","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood-2013-04-499335","article-title":"Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study","volume":"122","author":"Pintao","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0290","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7326\/0003-4819-107-1-42","article-title":"Protein S deficiency occurs in the nephrotic syndrome","volume":"107","author":"Vigano-D\u2019angelo","year":"1987","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0295","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0038-1657551","article-title":"Protein S deficiency","volume":"78","author":"Borgel","year":"1997","journal-title":"Thromb Haemost"},{"issue":"9 Suppl","key":"10.1016\/j.autrev.2025.103763_bb0300","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/00003246-200009001-00010","article-title":"The protein C pathway","volume":"28","author":"Esmon","year":"2000","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0305","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/0003-4819-102-6-814","article-title":"The hypercoagulable states","volume":"102","author":"Schafer","year":"1985","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0310","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-0038-1661440","article-title":"High plasma levels of protein C activity and antigen in the nephrotic syndrome","volume":"55","author":"Mannucci","year":"1986","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0315","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000184980","article-title":"Increased levels of protein C activity, protein C concentration, total and free protein S in nephrotic syndrome","volume":"49","author":"Vaziri","year":"1988","journal-title":"Nephron"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2025.103763_bb0320","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.thromres.2012.02.024","article-title":"TFPI-dependent activities of protein S","volume":"129","author":"Peraramelli","year":"2012","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0325","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00467-006-0061-2","article-title":"Tissue factor pathway inhibitor in childhood nephrotic syndrome","volume":"21","author":"Al-Mugeiren","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0330","first-page":"1020","article-title":"High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria","volume":"82","author":"Ari\u00ebns","year":"1999","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0335","first-page":"1283","article-title":"Antithrombin III level in children with nephrotic syndrome, its correlation to thromboembolic complications, and serum albumin level","volume":"32","author":"Hussein","year":"2021","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0340","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s004670050029","article-title":"Hemostatic problems and thromboembolic complications in nephrotic children","volume":"14","author":"Citak","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103763_bb0345","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00467-020-04904-w","article-title":"Determination of the value of albumin, anti-thrombin III, fibrinogen and D-dimer factors in the diagnosis of asymptomatic pulmonary embolism in patients with nephrotic syndrome","volume":"36","author":"Hoseiny Nejad","year":"2021","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0350","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4049\/jimmunol.137.5.1511","article-title":"The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy","volume":"137","author":"Cybulsky","year":"1986","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0355","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI112408","article-title":"Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy","volume":"77","author":"Cybulsky","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103763_bb0360","article-title":"Deposition of the membrane attack complex in healthy and diseased human kidneys","volume":"11","author":"Koopman","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103763_bb0365","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/S0021-9258(19)39666-8","article-title":"Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex","volume":"265","author":"Hamilton","year":"1990","journal-title":"J Biol Chem"},{"issue":"34","key":"10.1016\/j.autrev.2025.103763_bb0370","doi-asserted-by":"crossref","first-page":"18205","DOI":"10.1016\/S0021-9258(19)81346-7","article-title":"Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity","volume":"263","author":"Sims","year":"1988","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/j.autrev.2025.103763_bb0375","doi-asserted-by":"crossref","first-page":"14587","DOI":"10.1016\/S0021-9258(18)66911-X","article-title":"On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity","volume":"261","author":"Wiedmer","year":"1986","journal-title":"J Biol Chem"},{"issue":"28","key":"10.1016\/j.autrev.2025.103763_bb0380","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1016\/S0021-9258(19)76479-5","article-title":"Complement C5b-9-stimulated platelet secretion is associated with a Ca2+\u2212initiated activation of cellular protein kinases","volume":"262","author":"Wiedmer","year":"1987","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0385","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1038\/s41467-021-26366-w","article-title":"Structural basis of soluble membrane attack complex packaging for clearance","volume":"12","author":"Menny","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.autrev.2025.103763_bb0390","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1055\/s-0039-1693701","article-title":"Decoration of fibrin with extracellular chaperones","volume":"119","author":"Talens","year":"2019","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0395","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1538-7836.2009.03334.x","article-title":"Abnormal platelet function in C3-deficient mice","volume":"7","author":"Gushiken","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"16","key":"10.1016\/j.autrev.2025.103763_bb0400","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.autrev.2025.103763_bb0405","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1073\/pnas.1202588109","article-title":"Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2","volume":"109","author":"H\u00e9ja","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0410","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.molimm.2015.02.014","article-title":"MASP-1 of the complement system promotes clotting via prothrombin activation","volume":"65","author":"Jenny","year":"2015","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0415","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2567.2009.03200.x","article-title":"Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot","volume":"129","author":"Gulla","year":"2010","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0420","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4049\/jimmunol.1102916","article-title":"Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis","volume":"188","author":"La Bonte","year":"2012","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0425","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.4049\/jimmunol.0900879","article-title":"Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function","volume":"183","author":"Megyeri","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.948190","article-title":"Complement lectin pathway components MBL and MASP-1 promote haemostasis upon vessel injury in a microvascular bleeding model","volume":"13","author":"Golomingi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0435","first-page":"11","article-title":"Podocytes produce and secrete functional complement C3 and complement factor H","volume":"2020","author":"M\u00fchlig","year":"1833","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103763_bb0440","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"\u03b2\u2082-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0445","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V66.5.1086.1086","article-title":"beta 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway","volume":"66","author":"Schousboe","year":"1985","journal-title":"Blood"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2025.103763_bb0450","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0021-9150(87)90110-9","article-title":"Beta 2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation","volume":"63","author":"Nimpf","year":"1987","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0455","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0304-4165(86)90237-0","article-title":"Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I","volume":"884","author":"Nimpf","year":"1986","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0460","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4049\/jimmunol.2000398","article-title":"Cross-talk between the complement pathway and the contact activation system of coagulation: activated factor XI neutralizes complement factor H","volume":"206","author":"Puy","year":"2021","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0465","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2014-06-585430","article-title":"von Willebrand factor is a cofactor in complement regulation","volume":"125","author":"Feng","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073715","article-title":"The interaction between factor H and Von Willebrand factor","volume":"8","author":"Feng","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0475","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2013-04-495853","article-title":"The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status","volume":"123","author":"Rayes","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.autrev.2025.103763_bb0480","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13028","article-title":"C5a anaphylatoxin and its role in critical illness-induced organ dysfunction","volume":"48","author":"Wood","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.autrev.2025.103763_bb0485","first-page":"11","article-title":"The complement C3a and C3a receptor pathway in kidney diseases","volume":"2020","author":"Gao","year":"1875","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0490","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.4049\/jimmunol.173.6.4190","article-title":"Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells","volume":"173","author":"Braun","year":"2004","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0495","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12882-019-1509-5","article-title":"Complement activation products in the circulation and urine of primary membranous nephropathy","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0500","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12026-016-8790-1","article-title":"IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study","volume":"64","author":"Yang","year":"2016","journal-title":"Immunol Res"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0505","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1084\/jem.158.2.603","article-title":"Human platelet activation by C3a and C3a des-arg","volume":"158","author":"Polley","year":"1983","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018812","article-title":"Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets","volume":"6","author":"Martel","year":"2011","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0515","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.4049\/jimmunol.0902810","article-title":"Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1","volume":"184","author":"Hamad","year":"2010","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.autrev.2025.103763_bb0520","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.118.034600","article-title":"Functional relevance of the anaphylatoxin receptor C3aR for platelet function and arterial Thrombus formation Marks an intersection point between innate immunity and thrombosis","volume":"138","author":"Sauter","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0525","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0530","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0535","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.autrev.2025.103763_bb0540","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008951","article-title":"Plasminogen: an enigmatic zymogen","volume":"137","author":"Keragala","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.autrev.2025.103763_bb0545","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1074\/jbc.M111.323287","article-title":"Plasminogen is a complement inhibitor","volume":"287","author":"Barthel","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2025.103763_bb0550","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","article-title":"Complement activation in arterial and venous thrombosis is mediated by plasmin","volume":"5","author":"Foley","year":"2016","journal-title":"EBioMedicine"},{"issue":"24","key":"10.1016\/j.autrev.2025.103763_bb0555","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2017-06-788216","article-title":"In vivo-generated thrombin and plasmin do not activate the complement system in baboons","volume":"130","author":"Keshari","year":"2017","journal-title":"Blood"},{"issue":"01","key":"10.1016\/j.autrev.2025.103763_bb0560","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jth.12217","article-title":"The transition of prothrombin to thrombin","volume":"11 Suppl 1","author":"Krishnaswamy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0565","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/MBC.0000000000001130","article-title":"The role of thrombin in haemostasis","volume":"33","author":"Al-Amer","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0570","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0575","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.autrev.2025.103763_bb0580","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103763_bb0585","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2019.01590","article-title":"The human platelet as an innate immune cell: interactions between activated platelets and the complement system","volume":"10","author":"Eriksson","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0590","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.20041497","article-title":"Platelet activation leads to activation and propagation of the complement system","volume":"201","author":"Del Conde","year":"2005","journal-title":"J Exp Med"},{"issue":"16","key":"10.1016\/j.autrev.2025.103763_bb0595","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1073\/pnas.84.16.5873","article-title":"Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H","volume":"84","author":"Devine","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.autrev.2025.103763_bb0600","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/j.1538-7836.2007.02690.x","article-title":"Proteomic analysis of platelet alpha-granules using mass spectrometry","volume":"5","author":"Maynard","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0605","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2003-08-2804","article-title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions","volume":"103","author":"Coppinger","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.autrev.2025.103763_bb0610","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1538-7836.2008.03034.x","article-title":"Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets","volume":"6","author":"Hamad","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0615","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.13208","article-title":"The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation","volume":"14","author":"Kozarcanin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.autrev.2025.103763_bb0620","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.autrev.2025.103763_bb0625","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2025.103763_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119818","article-title":"Heparin: an old drug for new clinical applications","volume":"295","author":"Wang","year":"2022","journal-title":"Carbohydr Polym"},{"issue":"10","key":"10.1016\/j.autrev.2025.103763_bb0635","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.4049\/jimmunol.148.10.3210","article-title":"Heparin and modified heparin inhibit complement activation in vivo","volume":"148","author":"Weiler","year":"1992","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103763_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233644","article-title":"Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood","volume":"15","author":"Hogwood","year":"2020","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0645","first-page":"1141","article-title":"The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy via complement inhibition","volume":"108","author":"Wang","year":"2012","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.autrev.2025.103763_bb0650","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1046\/j.1523-1755.1999.00639.x","article-title":"Inhibition of glomerular cell apoptosis by heparin","volume":"56","author":"Ishikawa","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2025.103763_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115683","article-title":"Functional, proteomic and phenotypic in vitro studies evidence podocyte injury after chronic exposure to heparin","volume":"429","author":"Del\u00e9zay","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103763_bb0660","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/jth.13475","article-title":"Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism","volume":"14","author":"Arachchillage","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"9 Suppl","key":"10.1016\/j.autrev.2025.103763_bb0665","article-title":"Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation","volume":"94","author":"Gikakis","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.autrev.2025.103763_bb0670","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molimm.2014.06.031","article-title":"The complement system in human cardiometabolic disease","volume":"61","author":"Hertle","year":"2014","journal-title":"Mol Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103763_bb0675","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2018-06-856195","article-title":"Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications","volume":"133","author":"Kearney","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2025.103763_bb0680","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2019.239558","article-title":"Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk","volume":"106","author":"King","year":"2021","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2025.103763_bb0685","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0140-6736(15)60372-5","article-title":"Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes","volume":"385","author":"King","year":"2015","journal-title":"Lancet"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225000230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:04:02Z","timestamp":1741665842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225000230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":137,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1568997225000230"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103763","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement-coagulation crosstalk in idiopathic membranous nephropathy: The potential pathogenesis and therapeutic perspective","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103763"}}